Home LiteratureArticle Details
PMID: 12107831 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Targeting the cell cycle for cancer therapy.

British journal of cancer ·Vol. 87 ·No. 2 ·2002-07-15 ·Pages 129-33

Carnero A

Abstract

Most if not all neoplasias show a directly or indirectly deregulated cell cycle. Targeting its regulatory molecules, the cyclin-dependent kinases, as a therapeutic mode to develop new anticancer drugs, is being currently explored in both academia and pharmaceutical companies. The development of new compounds is being focused on the many features of the cell cycle with promising preclinical data in most fields. Moreover, a few compounds have entered clinical trials with excellent results maintaining the high hopes. Thus, although too early to provide a cell cycle target based new commercial drug, there is no doubt that it will be an excellent source of new anticancer compounds.

MeSH Terms
Adenovirus E2 Proteins/physiology Antineoplastic Agents/pharmacology Apoptosis/drug effects Cell Cycle/drug effects Cell Cycle Proteins/antagonists & inhibitors,physiology Cyclin-Dependent Kinases/antagonists & inhibitors,physiology Cysteine Endopeptidases DNA-Binding Proteins Drug Design Drug Evaluation E2F Transcription Factors Enzyme Inhibitors/pharmacology Genes, cdc Humans Multienzyme Complexes/antagonists & inhibitors Neoplasm Proteins/antagonists & inhibitors,physiology Neoplasms/drug therapy,pathology Proteasome Endopeptidase Complex Transcription Factors/physiology cdc25 Phosphatases/antagonists & inhibitors,physiology
Chemicals
Adenovirus E2 Proteins Antineoplastic Agents Cell Cycle Proteins DNA-Binding Proteins E2F Transcription Factors Enzyme Inhibitors Multienzyme Complexes Neoplasm Proteins Transcription Factors Cyclin-Dependent Kinases cdc25 Phosphatases Cysteine Endopeptidases Proteasome Endopeptidase Complex
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Carnero A
Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncologicas (CNIO), c/Melchor Fernandez Almagro no. 3, 28029 Madrid, Spain. acrnero@cnio.es
References (58)
58 references, click to expand
  1. The centrosome-associated Aurora/Ipl-like kinase family.
    Curr Top Dev Biol. 2000;49:331-42 PMID: 11005026
  2. Checkpoint pathways come of age.
    Cell. 1997 Dec 26;91(7):865-7 PMID: 9428508
  3. Cyclin-dependent kinase inhibitors: novel anticancer agents.
    Expert Opin Investig Drugs. 2000 Aug;9(8):1849-70 PMID: 11060782
  4. Ras proteins in the control of the cell cycle and cell differentiation.
    Cell Mol Life Sci. 2000 Oct;57(11):1613-36 PMID: 11092455
  5. Co-expression of E2F-2 enhances the p53 anti-cancer effect in human glioma cells.
    Int J Oncol. 2001 Feb;18(2):343-7 PMID: 11172602
  6. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
    Leukemia. 2001 Jan;15(1):1-9 PMID: 11243375
  7. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.
    J Clin Oncol. 2001 Apr 1;19(7):1985-92 PMID: 11283131
  8. Myc and the cell cycle.
    Front Biosci. 1998 Feb 15;3:d250-68 PMID: 9468463
  9. RAS pathways to cell cycle control and cell transformation.
    Front Biosci. 1998 Aug 6;3:d887-912 PMID: 9696882
  10. Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins.
    Cell. 1991 Dec 20;67(6):1181-94 PMID: 1836978
  11. Distinct roles for cyclin-dependent kinases in cell cycle control.
    Science. 1993 Dec 24;262(5142):2050-4 PMID: 8266103
  12. p53 and E2F-1 cooperate to mediate apoptosis.
    Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3602-6 PMID: 8170954
  13. G1 phase progression: cycling on cue.
    Cell. 1994 Nov 18;79(4):551-5 PMID: 7954821
  14. Mammalian G1 cyclins.
    Curr Opin Cell Biol. 1994 Dec;6(6):842-6 PMID: 7880531
  15. Cyclin-dependent kinases. CAK-handed kinase activation.
    Curr Biol. 1995 Jan 1;5(1):40-2 PMID: 7697347
  16. The retinoblastoma protein and cell cycle control.
    Cell. 1995 May 5;81(3):323-30 PMID: 7736585
  17. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector.
    Cancer Res. 1995 Aug 1;55(15):3250-3 PMID: 7614457
  18. Arrest at the G2/M transition of the cell cycle by protein-tyrosine phosphatase inhibition: studies on a neuronal and a glial cell line.
    J Cell Biochem. 1995 Nov;59(3):389-401 PMID: 8567756
  19. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2.
    Nature. 1996 Apr 11;380(6574):548-50 PMID: 8606778
  20. Inhibition of lung cancer proliferation by antisense cyclin D.
    Cancer Gene Ther. 1996 Mar-Apr;3(2):131-5 PMID: 8729912
  21. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A.
    Curr Biol. 1996 Jan 1;6(1):84-91 PMID: 8805225
  22. p53 in signaling checkpoint arrest or apoptosis.
    Curr Opin Genet Dev. 1996 Feb;6(1):12-8 PMID: 8791489
  23. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum.
    J Clin Invest. 1998 Jan 15;101(2):344-52 PMID: 9435306
  24. Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells.
    Oncogene. 1998 Jan 15;16(2):265-72 PMID: 9464545
  25. Inhibitors of the Cip/Kip family.
    Curr Top Microbiol Immunol. 1998;227:25-41 PMID: 9479824
  26. The INK4 family of CDK inhibitors.
    Curr Top Microbiol Immunol. 1998;227:43-55 PMID: 9479825
  27. The family of polo-like kinases.
    Prog Cell Cycle Res. 1996;2:107-14 PMID: 9552388
  28. Antisense phosphorothioate oligonucleotides specifically down-regulate cdc25B causing S-phase delay and persistent antiproliferative effects.
    Int J Cancer. 1998 May 29;76(5):720-8 PMID: 9610732
  29. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo.
    Nat Med. 1998 Jun;4(6):685-90 PMID: 9623977
  30. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
    J Clin Oncol. 1998 Sep;16(9):2986-99 PMID: 9738567
  31. Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells.
    Cancer Res. 1998 Nov 1;58(21):4811-6 PMID: 9809983
  32. Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth.
    Oncogene. 1998 Dec 24;17(25):3365-83 PMID: 9916999
  33. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists.
    Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4325-9 PMID: 10200261
  34. Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity.
    Oncogene. 1999 Mar 4;18(9):1663-76 PMID: 10208428
  35. Regulating the onset of mitosis.
    Curr Opin Cell Biol. 1999 Apr;11(2):267-73 PMID: 10209160
  36. Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells.
    Oncogene. 1996 Oct 3;13(7):1395-403 PMID: 8875977
  37. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors.
    J Mol Biol. 1999 Apr 16;287(5):821-8 PMID: 10222191
  38. The p53 pathway.
    J Pathol. 1999 Jan;187(1):112-26 PMID: 10341712
  39. CDK inhibitors: positive and negative regulators of G1-phase progression.
    Genes Dev. 1999 Jun 15;13(12):1501-12 PMID: 10385618
  40. Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases.
    Pharmacol Ther. 1999 May-Jun;82(2-3):279-84 PMID: 10454205
  41. Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target.
    Pharmacol Ther. 1999 May-Jun;82(2-3):285-92 PMID: 10454206
  42. Adenovirus-mediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in MDM2-overexpressing tumor cells.
    Clin Cancer Res. 1999 Aug;5(8):2242-50 PMID: 10473112
  43. Adenovirus-mediated E2F-1 gene transfer efficiently induces apoptosis in melanoma cells.
    Cancer. 1999 Nov 15;86(10):2021-33 PMID: 10570427
  44. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.
    J Clin Oncol. 2000 Jan;18(2):371-5 PMID: 10637252
  45. The hallmarks of cancer.
    Cell. 2000 Jan 7;100(1):57-70 PMID: 10647931
  46. The E2F transcription factors: key regulators of cell proliferation.
    Biochim Biophys Acta. 2000 Feb 14;1470(1):M1-12 PMID: 10656985
  47. Controlling the end of the cell cycle.
    Curr Opin Genet Dev. 2000 Feb;10(1):65-9 PMID: 10679389
  48. Preclinical and clinical development of cyclin-dependent kinase modulators.
    J Natl Cancer Inst. 2000 Mar 1;92(5):376-87 PMID: 10699068
  49. Cdc25 as a potential target of anticancer agents.
    Invest New Drugs. 2000 May;18(2):149-56 PMID: 10857994
  50. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication.
    J Biol Chem. 2000 Sep 15;275(37):28345-8 PMID: 10906320
  51. Cyclins and cyclin-dependent kinases: a biochemical view.
    Biochem J. 1995 Jun 15;308 ( Pt 3):697-711 PMID: 8948422
  52. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1.
    Curr Biol. 1997 Jan 1;7(1):71-80 PMID: 8999999
  53. Polo-like kinase, a novel marker for cellular proliferation.
    Am J Pathol. 1997 Apr;150(4):1165-72 PMID: 9094972
  54. p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth.
    Cancer Res. 1997 Apr 15;57(8):1442-6 PMID: 9108443
  55. Cdc25 protein phosphatases in cell proliferation.
    Biochim Biophys Acta. 1997 Apr 18;1332(2):M53-63 PMID: 9141461
  56. A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells.
    Oncogene. 1997 May 15;14(19):2283-9 PMID: 9178904
  57. Cyclin dependent kinase inhibitors.
    Cancer Surv. 1997;29:91-107 PMID: 9338098
  58. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.
    Curr Med Chem. 2000 Dec;7(12):1213-45 PMID: 11032968
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
DOI
10.1038/sj.bjc.6600458
Email
acrnero@cnio.es
Published
2002-07-15
Pages
129-33
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2376115
Subset
IM
External Links
PubMed source DOI: 10.1038/sj.bjc.6600458 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2